OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis → We recommended Nvidia in 2016, now we’re recommending this… (From Porter & Company) (Ad) Free ACUR Stock Alerts $0.03 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.00▼$0.0352-Week Range$0.00▼$0.05VolumeN/AAverage Volume811 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Acura Pharmaceuticals Stock (OTCMKTS:ACUR)Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.Read More ACUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACUR Stock News HeadlinesJune 5, 2024 | americanbankingnews.comAcura Pharmaceuticals (OTCMKTS:ACUR) Share Price Crosses Above Two Hundred Day Moving Average of $0.00May 27, 2024 | msn.comStocks To Watch, Shares in News: LIC, Lumax Auto, NMDC, IRCTC, NBCC, Yes Bank, ICICI Bank and moreMay 2, 2024 | yahoo.comJurors in Trump hush money trial hear recording of a call to buy affair story, AP ExplainsMay 2, 2024 | yahoo.comLIV Golf Houston 2024: Patrick Reed | CW39 HOUSTONMay 2, 2024 | yahoo.comMilwaukee Public Schools board director Aisha Carr announces mid-term resignationFebruary 28, 2024 | benzinga.comAcura Pharmaceuticals Stock (OTC:ACUR), Insider Trading ActivityFebruary 10, 2024 | yahoo.comRobert Kraft's foundation wants people to "stand up to hate" with Super Bowl adFebruary 5, 2024 | msn.comAmerican Honda reports 10.3% Y/Y sales growth in January amid a sequential declineJanuary 13, 2024 | morningstar.comAcura Pharmaceuticals Inc ACURNovember 20, 2023 | yahoo.comCumberland man jailed in alleged death threat against district court judgeSeptember 26, 2023 | news.yahoo.comMiami man distributed over $16 million of adulterated HIV drugs given to U.S. patientsAugust 24, 2023 | finance.yahoo.comAcura Pharmaceuticals, Inc. (ACUR)August 12, 2023 | forbes.comAcura Extended Warranty Review: Everything You Need To KnowJune 30, 2023 | au.finance.yahoo.comACUR - Acura Pharmaceuticals, Inc.May 31, 2023 | msn.comGot $1,000? 2 Amazing Growth Stocks That Could Help You Retire RicherMay 3, 2023 | marketwatch.comExploring the Growth Potential of the Opioid Drugs Market till 2031April 27, 2023 | marketwatch.comAzilsartan Medoxomil API Market Forecast to 2030April 22, 2023 | thestreet.com4 Stocks Under $10 Moving HigherApril 9, 2023 | benzinga.comGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023: One-Stop Source for Providing Real-Deal Information on Hundreds of TransactionsApril 9, 2023 | marketwatch.comOpioid Drugs Market Sales By 2030March 29, 2023 | marketwatch.comCalming and Sleeping Market Outlook and Forecast till 2028March 13, 2023 | thestreet.comAcura Stock Soars (ACUR)February 17, 2023 | marketwatch.comOpioid Drugs Market Forcast 2023 To 2028 : In-depth Research Analysis with Top Countries DataFebruary 13, 2023 | marketwatch.comAzilsartan Medoxomil API Market 2023-2029 Global Forecast with Top Key Players such as: Takeda, Lupin, Acura Labs, Metrochem APIFebruary 8, 2023 | marketwatch.comOpioid Drugs Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2028See More Headlines Company Calendar Last Earnings2/28/2020Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CUSIP00509L70 CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees9Year Founded1935Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.56 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,350,000Free Float52,947,000Market Cap$1.82 million OptionableNot Optionable Beta1.05 Social Links Key ExecutivesMr. Robert B. Jones (Age 65)CEO, President & Director Comp: $150kMr. Peter A. Clemens (Age 71)Senior VP, CFO & Secretary Comp: $200kMr. Robert A. Seiser CPA (Age 60)Ph.D., VP, Treasurer & Corporate Controller Comp: $210.2kKey CompetitorsEli Lilly and CompanyNYSE:LLYJohnson & JohnsonNYSE:JNJMerck & Co., Inc.NYSE:MRKAbbVieNYSE:ABBVPfizerNYSE:PFEView All Competitors ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed in 2024? Acura Pharmaceuticals' stock was trading at $0.0001 at the start of the year. Since then, ACUR stock has increased by 27,400.0% and is now trading at $0.0275. View the best growth stocks for 2024 here. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) released its quarterly earnings data on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.32 million for the quarter. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Adamis Pharmaceuticals (ADMP), Ekso Bionics (EKSO), VIVUS (VVUS), Fulcrum Therapeutics (FULC), (GBSN) (GBSN), Trevena (TRVN), AcelRx Pharmaceuticals (ACRX), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD). How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Acura Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Acura Pharmaceuticals: Acura Pharmaceutical Technologies Inc..Read More This page (OTCMKTS:ACUR) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Acura Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.